View Older Stories View More Recent Stories

May 13, 2021 04:10PM  Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 6, 2021 04:34PM Form SC 13D Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
May 5, 2021 04:40PM Form SC 13G Seres Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
May 3, 2021 06:30AM Affinia Therapeutics Closes $110 Million Series B Financing
Apr 29, 2021 02:39PM Chardan Acts as Exclusive Placement Agent in Forge Biologics' $120 Million Series B Financing
Apr 29, 2021 11:00AM Ceribell Announces Completion Of $53 Million Series C Financing
Apr 29, 2021 08:00AM Forge Biologics Announces Closing of $120 Million Series B Financing
Apr 29, 2021 03:53AM Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
Apr 29, 2021 03:00AM Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
Apr 28, 2021 09:07AM POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
Apr 28, 2021 07:30AM Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)
Apr 27, 2021 10:05AM AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
Apr 20, 2021 09:00AM Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Apr 19, 2021 08:00AM PepGen to Present a CureDuchenne Webinar on Unlocking the Potential of Exon Skipping Therapeutics for Duchenne Muscular Dystrophy
Apr 19, 2021 06:30AM Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19
Apr 16, 2021 04:36PM Form SC 13D Achilles Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 15, 2021 04:00AM Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
Apr 14, 2021 08:30AM Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies
Apr 13, 2021 07:00AM AavantiBio Deepens AAV Manufacturing Capabilities with Key Hires to Support Strategic Growth
Apr 12, 2021 07:30AM Antios Therapeutics Raises $96 Million in a Series B Financing
Apr 8, 2021 06:00AM Ventus Therapeutics Closes $100 Million Series B Financing
Apr 7, 2021 04:33PM Form SC 13G/A Trillium Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 7, 2021 04:32PM Form SC 13G/A Atea Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 7, 2021 04:31PM Form SC 13G Bolt Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Apr 7, 2021 08:14AM DTx Pharma to Participate in the 2021 Needham Virtual Healthcare Conference
Apr 7, 2021 08:00AM Metagenomi Extends Series A Financing from RA Capital and Welcomes Andrew Levin to Its Board of Directors
Apr 7, 2021 08:00AM Nucleix Secures $55 Million Funding Led by RA Capital Management and Additional Prominent Life Science Investors to Advance Lung EpiCheck® for Early Detection of Lung Cancer
Apr 7, 2021 07:00AM Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
Mar 31, 2021 04:05PM Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
Mar 31, 2021 04:05PM Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
Mar 31, 2021 10:00AM Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
Mar 31, 2021 07:00AM New Equilibrium Bio raises $10M from RA Capital for AI-powered quantum chemistry
Mar 30, 2021 05:05PM Form SC 13G/A Vaxcyte, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 30, 2021 08:00AM Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
Mar 30, 2021 07:00AM AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer
Mar 29, 2021 04:30PM Form SC 13D Connect Biopharma Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 25, 2021 05:00PM Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Mar 25, 2021 05:00AM Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders
Mar 24, 2021 04:31PM Form SC 13G PhaseBio Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 23, 2021 04:32PM Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 23, 2021 08:30AM PepGen to Present at Stifel's 3rd Annual CNS Day
Mar 22, 2021 02:30PM Research Alliance Corp. II, Sponsored by RA Capital Management, L.P., Announces Closing of $149.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option to Purchase
Mar 18, 2021 11:40AM IPO for SPAC Research Alliance Corp. II (RACB) Opened at $10.22
Mar 17, 2021 11:40PM Research Alliance Corp. II, Sponsored by RA Capital Management, L.P., Announces Pricing of $130 Million Initial Public Offering
Mar 15, 2021 04:38PM Form SC 13G/A Viridian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Mar 15, 2021 07:30AM Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
Mar 15, 2021 06:35AM POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I (RACA)
Mar 15, 2021 06:00AM Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
Mar 15, 2021 06:00AM Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
Mar 15, 2021 06:00AM PepGen to Present Late-Breaking Data from Novel Enhanced Delivery Oligonucleotide (EDO) Pipeline at 2021 Muscular Dystrophy Association Virtual Clinical and Scientific Conference
View More Recent Stories View Older Stories